Trial Profile
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Indatuximab ravtansine (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biotest Pharmaceuticals
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 31 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.